America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center.
Help employers find you! Check out all the jobs and post your resume.